{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:59:53Z","timestamp":1783601993075,"version":"3.55.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"41","license":[{"start":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T00:00:00Z","timestamp":1661558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100007405","name":"Danish Heart Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007405","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Danish Independent Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>A recent trial has shown that screening of men for cardiovascular disease (CVD) may reduce all-cause mortality. This study assesses the cost effectiveness of such screening vs. no screening from the perspective of European healthcare systems.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Randomized controlled trial-based cost-effectiveness evaluation with a mean 5.7 years of follow-up. Screening was based on low-dose computed tomography to detect coronary artery calcification and aortic\/iliac aneurysms, limb blood pressure measurement to detect peripheral artery disease and hypertension, telemetric assessment of the heart rhythm to detect atrial fibrillation, and measurements of the cholesterol and HgbA1c levels. Censoring-adjusted incremental costs, life years (LY), and quality-adjusted LY (QALY) were estimated and used for cost-effectiveness analysis. The incremental cost of screening for the entire health care sector was \u20ac207 [95% confidence interval (CI) \u221224; 438, P = 0.078] per invitee for which gains of 0.019 LY (95% CI \u22120.007; 0.045, P = 0.145) and 0.023 QALY (95% CI \u22120.001; 0.046, P = 0.051) were achieved. The corresponding incremental cost-effectiveness ratios were of \u20ac10 812 per LY and \u20ac9075 per QALY, which would be cost effective at probabilities of 0.73 and 0.83 for a willingness to pay of \u20ac20 000. Assessment of population heterogeneity showed that cost effectiveness could be more attractive for younger men without CVD at baseline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Comprehensive screening for CVD is overall cost effective at conventional thresholds for willingness to pay and also competitive to the cost effectiveness of common cancer screening programmes. The screening target group, however, needs to be settled.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehac488","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T06:38:30Z","timestamp":1661582310000},"page":"4392-4402","source":"Crossref","is-referenced-by-count":28,"title":["Cost effectiveness of population screening vs. no screening for cardiovascular disease: the Danish Cardiovascular Screening trial (DANCAVAS)"],"prefix":"10.1093","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3557-8550","authenticated-orcid":false,"given":"Rikke","family":"S\u00f8gaard","sequence":"first","affiliation":[{"name":"Elite Research Centre of Individualized Medicine in Arterial Disease (CIMA), Institute of Clinical Research, University of Southern Denmark , J.B. Winsl\u00f8ws Vej 4, Odense 5000 , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1285-4826","authenticated-orcid":false,"given":"Axel Cosmus Pyndt","family":"Diederichsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Elite Research Centre of Individualized Medicine in Arterial Disease (CIMA), Odense University Hospital , Odense 5000 , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars M","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry and Pharmacology, Elite Research Centre of Individualized Medicine in Arterial Disease (CIMA), Odense University Hospital , Odense 5000 , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jess","family":"Lambrechtsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Odense University Hospital , Svendborg 5700 , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flemming H","family":"Steffensen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Lillebaelt Hospital , Vejle 7100 , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9215-9796","authenticated-orcid":false,"given":"Lars","family":"Frost","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Diagnostic Centre, Regional Hospital Silkeborg , Silkeborg 8600 , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Egstrup","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Odense University Hospital , Svendborg 5700 , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazina","family":"Urbonaviciene","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Diagnostic Centre, Regional Hospital Silkeborg , Silkeborg 8600 , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0212-394X","authenticated-orcid":false,"given":"Martin","family":"Busk","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Lillebaelt Hospital , Vejle 7100 , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes S","family":"Lindholt","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic and Vascular Surgery, Elite Research Centre of Individualized Medicine in Arterial Disease (CIMA), Odense University Hospital , Odense 5000 , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,27]]},"reference":[{"key":"2022103123584829200_ehac488-B1","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/eurheartj\/ehy378","article-title":"Epidemiology report: trends in sex-specific cerebrovascular disease mortality in Europe based on WHO mortality data","volume":"40","author":"Shah","year":"2019","journal-title":"Eur Heart J"},{"key":"2022103123584829200_ehac488-B2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41569-021-00607-3","article-title":"Epidemiology of cardiovascular disease in Europe","volume":"19","author":"Townsend","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"2022103123584829200_ehac488-B3","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/eurheartj\/ehab892","article-title":"European Society of cardiology: cardiovascular disease statistics 2021","volume":"43","author":"Timmis","year":"2022","journal-title":"Eur Heart J"},{"key":"2022103123584829200_ehac488-B4","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2022103123584829200_ehac488-B5","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/CIRCRESAHA.116.309115","article-title":"Decline in cardiovascular mortality: possible causes and implications","volume":"120","author":"Mensah","year":"2017","journal-title":"Circ Res"},{"key":"2022103123584829200_ehac488-B6","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/eurheartj\/ehn554","article-title":"Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002","volume":"30","author":"Bjorck","year":"2009","journal-title":"Eur Heart J"},{"key":"2022103123584829200_ehac488-B7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/jech-2021-216581","article-title":"Effectiveness of the population-based \u2018check your health preventive programme\u2019 conducted in a primary care setting: a pragmatic randomised controlled trial","volume":"76","author":"Bjerregaard","year":"2022","journal-title":"J Epidemiol Community Health"},{"key":"2022103123584829200_ehac488-B8","doi-asserted-by":"crossref","first-page":"g3617","DOI":"10.1136\/bmj.g3617","article-title":"Effect of screening and lifestyle counselling on incidence of ischaemic heart disease in general population: Inter99 randomised trial","volume":"348","author":"Jorgensen","year":"2014","journal-title":"BMJ"},{"key":"2022103123584829200_ehac488-B9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/ije\/dyp315","article-title":"Rose's population strategy of prevention need not increase social inequalities in health","volume":"39","author":"McLaren","year":"2010","journal-title":"Int J Epidemiol"},{"key":"2022103123584829200_ehac488-B10","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1186\/s13063-015-1082-6","article-title":"The Danish cardiovascular screening trial (DANCAVAS): study protocol for a randomized controlled trial","volume":"16","author":"Diederichsen","year":"2015","journal-title":"Trials"},{"key":"2022103123584829200_ehac488-B11","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/bjs.11135","article-title":"Baseline findings of the population-based, randomized, multifaceted danish cardiovascular screening trial (DANCAVAS) of men aged 65\u201374 years","volume":"106","author":"Lindholt","year":"2019","journal-title":"Br J Surg"},{"key":"2022103123584829200_ehac488-B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2208681","article-title":"Five-year outcomes of the comprehensive population-based randomized danish cardiovascular screening (DANCAVAS) trial","author":"Lindholt","year":"2022","journal-title":"N Engl J Med"},{"key":"2022103123584829200_ehac488-B13","doi-asserted-by":"crossref","first-page":"e067975","DOI":"10.1136\/bmj-2021-067975","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"376","author":"Husereau","year":"2022","journal-title":"BMJ"},{"key":"2022103123584829200_ehac488-B14","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1093\/eurheartj\/ehv251","article-title":"The high-density lipoprotein-adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30,824 Europeans: the Copenhagen general population study","volume":"36","author":"Mortensen","year":"2015","journal-title":"Eur Heart J"},{"key":"2022103123584829200_ehac488-B15","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1016\/S0140-6736(17)32250-X","article-title":"Population screening and intervention for vascular disease in Danish men (VIVA): a randomised controlled trial","volume":"390","author":"Lindholt","year":"2017","journal-title":"Lancet"},{"key":"2022103123584829200_ehac488-B16","doi-asserted-by":"crossref","first-page":"e048192","DOI":"10.1136\/bmjopen-2020-048192","article-title":"Changes in life expectancy and lifespan variability by income quartiles in four Nordic countries: a study based on nationwide register data","volume":"11","author":"Bronnum-Hansen","year":"2021","journal-title":"BMJ Open"},{"key":"2022103123584829200_ehac488-B17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/heartjnl-2019-315129","article-title":"Progress in reducing inequalities in cardiovascular disease mortality in Europe","volume":"106","author":"Di Girolamo","year":"2020","journal-title":"Heart"},{"key":"2022103123584829200_ehac488-B18","first-page":"717","article-title":"The Danish unique personal identifier and the Danish civil registration system as a tool for research and quality improvement","volume":"31","author":"Mainz","year":"2019","journal-title":"Int J Qual Health Care"},{"key":"2022103123584829200_ehac488-B19","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1177\/1403494809105286","article-title":"Danish EQ-5D population norms","volume":"37","author":"Sorensen","year":"2009","journal-title":"Scand J Public Health"},{"key":"2022103123584829200_ehac488-B20","author":"S\u00f8gaard","year":"2022"},{"key":"2022103123584829200_ehac488-B21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1403494810394718","article-title":"The Danish national health service register","volume":"39","author":"Andersen","year":"2011","journal-title":"Scand J Public Health"},{"key":"2022103123584829200_ehac488-B22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1403494811401482","article-title":"The Danish national patient register","volume":"39","author":"Lynge","year":"2011","journal-title":"Scand J Public Health"},{"key":"2022103123584829200_ehac488-B23","first-page":"798","article-title":"Data resource profile: the Danish national prescription registry","volume":"46","author":"Pottegard","year":"2017","journal-title":"Int J Epidemiol"},{"key":"2022103123584829200_ehac488-B24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2307\/2533947","article-title":"Estimating medical costs from incomplete follow-up data","volume":"53","author":"Lin","year":"1997","journal-title":"Biometrics"},{"key":"2022103123584829200_ehac488-B25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/hec.4730030505","article-title":"Costs, effects and C\/E-ratios alongside a clinical trial","volume":"3","author":"van Hout","year":"1994","journal-title":"Health Econ"},{"key":"2022103123584829200_ehac488-B26","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/(SICI)1099-1050(199812)7:8<723::AID-HEC392>3.0.CO;2-O","article-title":"Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane","volume":"7","author":"Briggs","year":"1998","journal-title":"Health Econ"},{"key":"2022103123584829200_ehac488-B27","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1177\/0272989X98018002S09","article-title":"Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis","volume":"18","author":"Stinnett","year":"1998","journal-title":"Med Decis Making"},{"key":"2022103123584829200_ehac488-B28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/sim.1347","article-title":"Incremental net benefit in randomized clinical trials with quality-adjusted survival","volume":"22","author":"Willan","year":"2003","journal-title":"Stat Med"},{"key":"2022103123584829200_ehac488-B29","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1191\/0962280202sm304ra","article-title":"Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods","volume":"11","author":"O'Brien","year":"2002","journal-title":"Stat Methods Med Res"},{"key":"2022103123584829200_ehac488-B30","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/CIRCOUTCOMES.114.001240","article-title":"Quantifying the utility of taking pills for cardiovascular prevention","volume":"8","author":"Hutchins","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2022103123584829200_ehac488-B31","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/bjs.10872","article-title":"Cost-effectiveness of population-based vascular disease screening and intervention in men from the viborg vascular (VIVA) trial","volume":"105","author":"Sogaard","year":"2018","journal-title":"Br J Surg"},{"key":"2022103123584829200_ehac488-B32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ejvs.2018.04.016","article-title":"Role of experience with preventive medication and personal risk attitude in non-attendance at triple vascular screening","volume":"56","author":"Hansen","year":"2018","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2022103123584829200_ehac488-B33","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/heartjnl-2018-314103","article-title":"Individual preferences on the balancing of good and harm of cardiovascular disease screening","volume":"105","author":"Hansen","year":"2019","journal-title":"Heart"},{"key":"2022103123584829200_ehac488-B34","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40271-019-00364-z","article-title":"Do non-participants at screening have a different threshold for an acceptable benefit-harm ratio than participants? Results of a discrete choice experiment","volume":"12","author":"Hansen","year":"2019","journal-title":"Patient"},{"key":"2022103123584829200_ehac488-B35","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/ehjqcco\/qcab005","article-title":"Estimating the cost-effectiveness of screening a general population for cardiovascular risk with high-sensitivity troponin-I","volume":"8","author":"Julicher","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2022103123584829200_ehac488-B36","doi-asserted-by":"crossref","first-page":"466","DOI":"10.2459\/JCM.0000000000001314","article-title":"Detecting the vulnerable carotid plaque: the carotid artery multimodality imaging prognostic study design","volume":"23","author":"Gargani","year":"2022","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2022103123584829200_ehac488-B37","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1007\/s00330-021-08422-7","article-title":"Can we increase efficiency of CT lung cancer screening by combining with CVD and COPD screening? Results of an early economic evaluation","volume":"32","author":"Behr","year":"2022","journal-title":"Eur Radiol"},{"key":"2022103123584829200_ehac488-B38","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1183\/09031936.00123410","article-title":"Long-term effects of lung cancer computed tomography screening on health-related quality of life: the NELSON trial","volume":"38","author":"van den Bergh","year":"2011","journal-title":"Eur Respir J"},{"key":"2022103123584829200_ehac488-B39","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1513\/AnnalsATS.201301-007OC","article-title":"Quality of life and healthcare use in a randomized controlled lung cancer screening study","volume":"10","author":"Mazzone","year":"2013","journal-title":"Ann Am Thorac Soc"},{"key":"2022103123584829200_ehac488-B40","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/epirev\/mxr004","article-title":"Cost-effectiveness of colorectal cancer screening","volume":"33","author":"Lansdorp-Vogelaar","year":"2011","journal-title":"Epidemiol Rev"},{"key":"2022103123584829200_ehac488-B41","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/j.cgh.2019.01.014","article-title":"Cost-effectiveness of colorectal cancer screening strategies \u2013 a systematic review","volume":"17","author":"Ran","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022103123584829200_ehac488-B42","doi-asserted-by":"crossref","first-page":"f2618","DOI":"10.1136\/bmj.f2618","article-title":"Cost effectiveness of the NHS breast screening programme: life table model","volume":"346","author":"Pharoah","year":"2013","journal-title":"BMJ"},{"key":"2022103123584829200_ehac488-B43","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ijc.34000","article-title":"Finding the optimal mammography screening strategy: a cost-effectiveness analysis of 920 modelled strategies","volume":"151","author":"Kregting","year":"2022","journal-title":"Int J Cancer"},{"key":"2022103123584829200_ehac488-B44","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12885-017-3974-1","article-title":"Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models","volume":"18","author":"Sanghera","year":"2018","journal-title":"BMC Cancer"},{"key":"2022103123584829200_ehac488-B45","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s10198-021-01422-w","article-title":"Cost-effectiveness of screening smokers and ex-smokers for lung cancer in the Netherlands in different age groups","volume":"23","author":"Al Khayat","year":"2022","journal-title":"Eur J Health Econ"},{"key":"2022103123584829200_ehac488-B46","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/bjs.9825","article-title":"Baseline prevalence of abdominal aortic aneurysm, peripheral arterial disease and hypertension in men aged 65\u201374 years from a population screening study (VIVA trial)","volume":"102","author":"Grondal","year":"2015","journal-title":"Br J Surg"},{"key":"2022103123584829200_ehac488-B47","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ejvs.2018.09.023","article-title":"Adherence to prescribed drugs among 65\u201374 year old men diagnosed with abdominal aortic aneurysm or peripheral arterial disease in a screening trial: a VIVA substudy","volume":"57","author":"Qvist","year":"2019","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2022103123584829200_ehac488-B48","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/CIRCRESAHA.118.313220","article-title":"Adherence in hypertension","volume":"124","author":"Burnier","year":"2019","journal-title":"Circ Res"},{"key":"2022103123584829200_ehac488-B49","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/eurheartj\/ehz859","article-title":"European Society of cardiology: cardiovascular disease statistics 2019","volume":"41","author":"Timmis","year":"2020","journal-title":"Eur Heart J"},{"key":"2022103123584829200_ehac488-B50","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehac488\/45568208\/ehac488.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/41\/4392\/46683390\/ehac488.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/41\/4392\/46683390\/ehac488.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T23:59:49Z","timestamp":1667260789000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/43\/41\/4392\/6677139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,27]]},"references-count":50,"journal-issue":{"issue":"41","published-online":{"date-parts":[[2022,8,27]]},"published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehac488","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,8,27]]}}}